Project Details
Description
Application prepared for Round 8 and resubmitted CRC-P for Round 9 and was successful. Partner SME is Glytherix a spin-off from Minomic.
Radioimmunotherapies show great promise in treating lethal cancers but are challenging to manufacture and deliver due to the short half-life of the radioisotope. This project brings together SMEs, Universities and Government research organisations to pioneer the routine development of monoclonal antibodies and scalable manufacturing processes to manufacture “shake and bake” kits that allow on-site, on-demand radiolabelling of antibodies in any hospital radiopharmacy. Glytherix’s Miltuximab anti-cancer antibody will be used as a testbed for the entire production process. The radiolabelled antibody will be tested in an Australian clinical trial to prove the safety and efficacy of this product in the treatment of cancer patients
Radioimmunotherapies show great promise in treating lethal cancers but are challenging to manufacture and deliver due to the short half-life of the radioisotope. This project brings together SMEs, Universities and Government research organisations to pioneer the routine development of monoclonal antibodies and scalable manufacturing processes to manufacture “shake and bake” kits that allow on-site, on-demand radiolabelling of antibodies in any hospital radiopharmacy. Glytherix’s Miltuximab anti-cancer antibody will be used as a testbed for the entire production process. The radiolabelled antibody will be tested in an Australian clinical trial to prove the safety and efficacy of this product in the treatment of cancer patients
| Acronym | CRC-P round 9 |
|---|---|
| Status | Finished |
| Effective start/end date | 1/07/20 → 30/06/23 |